Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetically Engineered Virus-Specific CTLs for Viral Infections in Immunosuppressed Cancer Patients
NCT05101213Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Virus-specific Cytotoxic T-lymphocytes in adenovirus infection, BK polyomavirus infection, cytomegalovirus infection (CMV) and 2 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival at 1 year. Started Jan 2023; status: terminated.
02
Drugs
Virus-specific Cytotoxic T-lymphocytes
03
Conditions
adenovirus infectionBK polyomavirus infectioncytomegalovirus infection (CMV)progressive multifocal leukoencephalopathy (PML)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05101213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101213.